Somatostatin and its use

Czech version

Authors: J. Špičák
Authors‘ workplace: Klinika hepatogastroenterologie, IKEM, Praha
Published in: Gastroent Hepatol 2012; 66(6): 458-464
Category: Clinical and Experimental Gastroenterology: Review Article

Overview

Somatostatin was discovered more than 40 years ago. It is a peptide with different prevailingly inhibitory effect. Two basic molecules of somatostatin differ particularly in the distribution and length of their action. Somatostatin acts as a hormone, a paracrine and autocrine factor and as a neurotransmitter. The highest concentration of somatostatin producing cells is found in the stomach, duodenum and pancreas. Somatostatin inhibits all, mainly pancreatic and gastric exocrine and endocrine secretion, modulates immunity and affects differentiation and other central nervous system functions. In clinical practice, somatostatin and its longer acting analogues can be used in oesophageal variceal bleeding. It reduces splanchnic circulation due to its direct effect on the cells of the smooth muscle. Thanks to the inhibition of the pancreatic secretion it can be used in the treatment of fistulas and in their prevention after pancreatic surgery. Somatostatin reduces the risk of pancreatitis after ERCP. It has both a symptomatic and inhibitory effect on neuroendocrine tumours. In the CzechRepublic it also plays a role as an OctreoScan in diagnostics. Somatostatin is also used in acromegaly, meningioma, polycystosis, angiodysplasia, Cushing syndrome and for ascites of unknown origin.

Key words:
somatostatin – portal hypertension – pancreatitis – secretion – endoleak – fistula

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
22. 8. 2012

Accepted:
30. 8. 2012

Sources

1. Holt RIG, McGregor AM. Somatostatin: from basic science to clinical application. Hong Kong: Excerpta Medica 1997: 3–146.

2. Low MJ. Somatostatin. In Henry HL, Norman AW. Encyclopedia of hormones. San Diego: Elsevier Science 2003: 379–388.

3. Vlachogiannakos J, Kougioumtzian A, Triantos C et al. Clinical trial: The effect of somatostatin vs octreotide in preventing post-endoscopic increase in hepatic venous pressure gradient in cirrhotics with bleeding varices. Aliment Pharmacol Ther 2007; 26(11–12): 1479–1487.

4. Palazón JM, Such J, Sánchez-Payá J et al. A comparison two different dosages of a somatostatin combined with sclerotherapy for the treatment of acute esophageal variceal bleeding: a prospective randomized trial. Rev Esp Enferm Dig 2006; 98(4): 249–254.

5. Moitinho E, Planas R, Banares R et al. Multicenter randomized trial comparing different schedule of somatostatin in the treatment of acute variceal bleeding. J Hepatol 2001; 35(6): 712–718.

6. Seo YS, Um SH, Hyun JJ et al. A prospective study comparing the efficacy of early administration of terlipressin and somatostatin for the control of acute variceal bleeding in patiens with cirrhosis. Korean J Hepatol 2006; 12(3): 373–384.

7. D´Amico G, Pagliaro L, Pietrosi G et al. Emergency sclerotherapy versus vasoactive drug for bleeding oesophageal varices in cirrhotic patiens. Cochrane Database Syst Rev 2010; (3): CD002233.

8. Wells M, Chande N, Adams P et al. Meta-analysis: vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther 2012; 35(11): 1267–1278.

9. Kalambokis G, Economou M, Paraskevi K et al. Effects of somatostatin, terlipressin and somatostatin plus terlipressin on portal and systemic hemodynamics and renal sodium excretion in patiens with cirrhosis. J Gastroenterol Hepatol 2005; 20(7): 1075–1081.

10. Pracovní skupina pro portální hypertenzi. Doporučený postup ČHS pro diagnostiku a léčbu krvácení do zažívacího traktu při portální hypertenzi. www.ces-hep.cz

11. García-Tsao G, Lim J. Management and treatment of patients with cirrhosis and portal hypertension: Recommendations from the department of veterans affairs hepatitis-C resource center program and the national hepatitis C program. Am J Gastroenterol 2009; 104(7): 1802–1829.

12. de Franchis R. Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on metodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53(4): 762–768.

13. Katsinelos P, Fasoulas K, Paroutoglou G et al. Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatits: a randomized, double blind, placebo-controlled trial. Endoscopy 2012; 44(1): 53–59.

14. Omata F, Deshpande G, Tokuda Y et al. Meta-analysis: Somatostatin or its long--lasting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis. J Gastroenterol 2012; 45(8): 885–895.

15. Ramos-De la Medina A, Sarr MG. Somatostatin analogues in prevention of pancreas-related complications after pancreatic resection. J Hepatobiliary Pancreas Surg 2006; 13(3): 190–193.

16. Gans SL, van Westreenen HL, Kiewiet JJ et al. Systematic review and meta-analysis of somatostatin analogues for the treatment of pancreatic fistula. British J Surg 2012; 99(6): 754–760.

17. Coughlin S, Roth L, Lurati G et al. Somatostatin analogues for the treatment of enterocutaneous fistulas: a systematic review and metaanalysis. World J Surg 2012; 36(5): 1016–1029.

18. Katsourakis A, Zezos P, Noussios G et al. Does prophylactic administration of somatostatin decrease the rate of complications after pancreatic resection? A clinical and electron microscopy study. Pancreas 2012; Epub ahead of print.

19. Gurusamy KS, Koti R, Fusai G et al. Somatostatin analogues for pancreatic surgery. Cochrane Database Syst Rev 2012; 6: CD008370.

20. Low MJ. The somatostatin neuroendoscrinne system: physiology and clinical relevance in gastrointestinal and pancreatic disorders. Best Practice Res Clin Endocrin Metabolism 2004; 18(4): 607–622.

21. Koopmans KP, Glaudemans AW. Rationale for the use of radiolabelled peptides kin diagnosis and therapy. Eur J Nucl Med Mol Imaging 2012; 39 (SupplI): S4–S10.

22. Laverman P, Sosabowski JK, Boerman OC et al. Radiolabeled peptides for oncological diagnosis. Eur J Nucl Med Mol Imaging 2012; 39 (Suppl I): S78–S92.

23. Rossi RE, Massironi S, Spampatii MP et al. Treatment of liver metastases in patiens with digestive neuroendocrine tumors. J Gastrointest Surg 2012; Epub ahead of print.

24. Niina Y, Fujimori N, Nakamura T et al. The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1. Gut Liver 2012; 6(3): 287–294.

25. Bon C, Aparicio T, Vincent M et al. Long-acting somatostatin analogues decrease blood transfusion requirements in patients with refractory gastrointestinal bleeding associated with angiodysplasia. Aliment Pharmacol Ther 2012; 36(6): 587–593.

26. Annunziata M, Luque RM, Durán-Prado M et al. Somatostatin and somatostatin analogues reduce PDGF-induced endometrial cell proliferation and motility. Hum Reprod 2012; 27(7): 2117–2129.

27. Grasso LFS, Pivonello R, Colao A. Somatostatin analogs as a first-line treatment in acromegaly. When is it appropriate? Curr Opin Endocrinol Diabetes Obes 2012; 19(4): 288–294.

28. Toulis KA, Goulis DG, Msaouel P et al. Dexamethasone plus somatostatin-analog manipulation as bone metastasis microenvironment-targeting therapy for the treatment of castration-resistant prostate cancer: A meta-analysis of uncontrolled studies Anticancer Research 2012; 32(8): 3283–3290.

29. Chamberlain MC, Barnholz-Sloan JS. Medical treatment of recurrent meningiomas. Expert Rev Neurother 2011; 11(10): 1425–1432.

30. Fleseriu M, Petersenn S. Medical treatment of Cushing´s disease: chat is the future? Pituitary 2012; Epub ahead of print.

31. Hogan MC, Masyuk TV, Page L et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant 2012; Epub ahead of print.

32. Chrispijn M, Nevens F, Gevers TJG et al. The long-term outcome of patiens with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther 2012; 35(2): 266–274.

33. Van Assche G, Ferrante M, Vermeire S et al. Octreotide for the treatment of diarrhoe in patients with ileal pouch anal anastomosis. Colorectal Dis 2012; 14(4): 181–186.

34. Yildirim AE, Altun R, Can S et al. Idiopathic chylous ascites treated with total parenteral nutrition and octreotide. Eur J Gastroenterol Hepatol 2011; 23(10): 961–963.